Eli Lilly’s current 87.5% “No” odds on licensing Peptron’s SmartDepot sustained-release microsphere platform by October 7 reflect the strictly evaluative nature of their October 2024 agreement. That deal provided only a limited non-exclusive R&D license for applying ultrasonic spray-dried PLGA microspheres to Lilly’s peptide candidates, with any commercial technology transfer or binding license explicitly deferred pending successful feasibility data. Nearly two years of joint work, recently expanded to CNS indications, have produced preclinical validation and in-vivo studies but no announced transition to commercialization. Lilly retains termination rights with 30 days’ notice, and competing long-acting efforts such as its Camurus FluidCrystal partnership add uncertainty. With weeks remaining before the deadline and no last-minute catalysts reported, traders see insufficient momentum for a definitive commercial agreement.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s current 87.5% “No” odds on licensing Peptron’s SmartDepot sustained-release microsphere platform by October 7 reflect the strictly evaluative nature of their October 2024 agreement. That deal provided only a limited non-exclusive R&D license for applying ultrasonic spray-dried PLGA microspheres to Lilly’s peptide candidates, with any commercial technology transfer or binding license explicitly deferred pending successful feasibility data. Nearly two years of joint work, recently expanded to CNS indications, have produced preclinical validation and in-vivo studies but no announced transition to commercialization. Lilly retains termination rights with 30 days’ notice, and competing long-acting efforts such as its Camurus FluidCrystal partnership add uncertainty. With weeks remaining before the deadline and no last-minute catalysts reported, traders see insufficient momentum for a definitive commercial agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s current 87.5% “No” odds on licensing Peptron’s SmartDepot sustained-release microsphere platform by October 7 reflect the strictly evaluative nature of their October 2024 agreement. That deal provided only a limited non-exclusive R&D license for applying ultrasonic spray-dried PLGA microspheres to Lilly’s peptide candidates, with any commercial technology transfer or binding license explicitly deferred pending successful feasibility data. Nearly two years of joint work, recently expanded to CNS indications, have produced preclinical validation and in-vivo studies but no announced transition to commercialization. Lilly retains termination rights with 30 days’ notice, and competing long-acting efforts such as its Camurus FluidCrystal partnership add uncertainty. With weeks remaining before the deadline and no last-minute catalysts reported, traders see insufficient momentum for a definitive commercial agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s current 87.5% “No” odds on licensing Peptron’s SmartDepot sustained-release microsphere platform by October 7 reflect the strictly evaluative nature of their October 2024 agreement. That deal provided only a limited non-exclusive R&D license for applying ultrasonic spray-dried PLGA microspheres to Lilly’s peptide candidates, with any commercial technology transfer or binding license explicitly deferred pending successful feasibility data. Nearly two years of joint work, recently expanded to CNS indications, have produced preclinical validation and in-vivo studies but no announced transition to commercialization. Lilly retains termination rights with 30 days’ notice, and competing long-acting efforts such as its Camurus FluidCrystal partnership add uncertainty. With weeks remaining before the deadline and no last-minute catalysts reported, traders see insufficient momentum for a definitive commercial agreement.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions